Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
PTD-DBM15 residues (approx.)RRRRRRRRYKQFRDHEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.Also known as: PTD-DBM, CXXC5-Dvl disrupting peptide
One foundational study in mice. Zero human clinical trials. PTD-DBM (Protein Transduction Domain-fused Dishevelled Binding Motif) is a topical peptide designed at Yonsei University to reactivate Wnt/beta-catenin signaling in balding scalps by blocking the CXXC5-Dvl interaction. The 2017 mouse data [1] showed new follicle formation when combined with valproic acid. That result hasn't translated to humans yet, and the original developer has moved on to a small molecule successor called KY19382. Experimental hair loss researchers still test it, but community results have been overwhelmingly disappointing so far.
New follicle formation in a mouse wound model. That single result from 2017 put PTD-DBM on the map for experimental hair loss research. PTD-DBM (Protein Transduction Domain-fused Dishevelled Binding Motif, CAS not yet assigned) is a synthetic peptide that blocks the protein-protein interaction between CXXC5 and Dishevelled (Dvl) at the upstream end of the Wnt/beta-catenin signaling pathway. CXXC5 is a zinc finger protein overexpressed in balding scalps. It suppresses Wnt signaling by sequestering Dvl. PTD-DBM competes for that binding site, restoring beta-catenin nuclear translocation and downstream transcription of hair growth genes. Cho and colleagues at Yonsei University published the foundational study in the Journal of Investigative Dermatology (2017)[1]. Topical PTD-DBM combined with valproic acid produced wound-induced hair follicle neogenesis (WIHN) in mice within 28 days. The peptide also upregulated beta-catenin in cultured human dermal papilla cells. A 2023 paper [2] confirmed CXXC5 mediates DHT-induced alopecia via PGD2 signaling, adding mechanistic weight to the target. Real-world use tells a different story. Community reports across tressless.com, HairLossTalk, and r/HairlossResearch consistently describe months of daily application with no visible results. Cold chain failures, concentration uncertainty, and the peptide's ~2.5 kDa molecular weight (limiting intact skin penetration) likely contribute to this gap. Dr. Kang-Yell Choi's lab has since pivoted to KY19382 [3], a small molecule that outperformed PTD-DBM plus valproic acid in a 2023 comparison. The peptide is no longer the active pipeline compound from its own creator.
CXXC5 is the molecular brake. PTD-DBM removes it. In healthy hair follicles, the Wnt/beta-catenin pathway drives the anagen (growth) phase of the hair cycle. Beta-catenin enters the nucleus, activates TCF/LEF transcription factors, and switches on genes responsible for follicle cycling and dermal papilla maintenance. In androgenetic alopecia, CXXC5 is overexpressed. This zinc finger protein binds to Dishevelled (Dvl), a key upstream scaffold in Wnt signaling, and blocks the pathway before it reaches beta-catenin. PTD-DBM is a synthetic peptide engineered to mimic the Dvl-binding domain of CXXC5. It competes for the same binding site on Dvl, displacing CXXC5 and freeing the pathway. Beta-catenin accumulates, translocates to the nucleus, and reactivates downstream transcription. The PTD portion (an octa-arginine protein transduction domain) enables the peptide to cross cell membranes when applied topically. Valproic acid enters the picture at a different node. VPA inhibits GSK-3-beta, the kinase that phosphorylates beta-catenin and tags it for degradation. PTD-DBM works upstream (removing CXXC5 from Dvl); VPA works downstream (preventing beta-catenin destruction). Mouse WIHN data from PMID 28595998 confirmed the combination outperformed either compound alone. That dual-node activation is the mechanistic rationale behind every community protocol pairing these two.
Preclinical evidence only. Foundational 2017 paper [1] demonstrated PTD-DBM + valproic acid produces wound-induced hair neogenesis (WIHN) in mice and upregulates beta-catenin in human dermal papilla cells in culture. No human clinical trial published. Original developer (Dr. Kang-Yell Choi, Yonsei University) has abandoned PTD-DBM for small molecule successor KY19382. Evidence base is narrow (~5 direct papers, ~15 broader CXXC5/Wnt papers).
PMID 28595998: Cho YC et al. J Invest Dermatol 2017. First demonstration: topical PTD-DBM + valproic acid promotes WIHN in a mouse wound model and upregulates beta-catenin/Wnt target genes in human dermal papilla cells in vitro. Remains the sole foundational efficacy study.
No human clinical trial. All efficacy data from murine wound models or cell culture. Small molecule successor KY19382 (PMID 33751552) outperformed PTD-DBM+VPA in 2023 (PMC9954685) and its developer has pivoted away from the peptide. High MW (~2.5 kDa) limits topical skin penetration without microneedling. No formal carcinogenicity study; Wnt/beta-catenin is proto-oncogenic when dysregulated. Half-life and topical PK not established.
Theoretically exciting but practically disappointing. Most consistent real-world finding: no visible results after months of use. Sourcing difficulties (cold chain, stability, concentration uncertainty) undermine real-world reliability. Small experimental contingent continues testing PTD-DBM + VPA + microneedling stacks with inconclusive results.
Preclinical science demonstrates mechanistic efficacy in mice and human dermal papilla cells in culture, but community human use consistently fails to replicate meaningful results. No human trial bridges this gap. Divergence likely reflects: inadequate topical bioavailability without microneedling, widespread daily vs. weekly dosing confusion, product degradation from cold chain failures, and genuine mouse-to-human translatability challenges. Dr. Choi's lab pivot to KY19382 implicitly acknowledges these translation limitations.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 500mcg | Daily |
| Moderate | 1mg | Daily |
| Aggressive | 1mg | Daily |
Your first vial is probably going to be a 5 mg lyophilized powder. Reconstitute in 10 mL of sterile water for a 0.5 mg/mL solution, or 5 mL for 1 mg/mL. Draw 1 mL per session with a syringe and apply directly to the scalp (no injection needed). That gives you 500 mcg per application at the lower concentration. A 5 mg vial at daily use lasts about 10 days at 0.5 mg/mL, or 5 days at 1 mg/mL. The thing most beginners miss: this peptide degrades fast once reconstituted. Use it within 14 days at 2 to 8 degrees Celsius. Lyophilized stock should stay at minus 20 degrees. If your vendor shipped without an ice pack, assume the product is compromised. Daily application is the community standard. Weekly dosing (which some guides mistakenly recommend) produces subclinical Wnt exposure. Apply to clean, dry scalp; avoid washing for 4 hours. If you're adding valproic acid, apply PTD-DBM first, wait 15 to 20 minutes, then apply VPA.
Apply topically for 12 weeks to assess response. Can be extended if well-tolerated. Frequency may be reduced from weekly to every 10-15 days after 2 months. Often paired with valproic acid topical and microneedling 1-2x/week.
No long-term safety data for sustained Wnt/beta-catenin activation via CXXC5 blockade in humans. Wnt pathway is proto-oncogenic when chronically dysregulated; formal carcinogenicity study not conducted for PTD-DBM. CXXC5 is also expressed in sebaceous glands and chronic blockade may cause sebum dysregulation. Cycling at 12 weeks on / 4 weeks off allows scalp health assessment and provides a break from the protocol.
Or use the universal Peptide Calculator for any peptide.
Expected: Reduced shedding in responders; modest density improvement possible by weeks 9-12. Majority of users report no visible change at this dose without VPA or microneedling.
Monitor: Photograph scalp at baseline and every 4 weeks under identical lighting and angle. Use trichoscopy ruler if available.
Reconstitute one 5 mg vial with 10 mL sterile water for 0.5 mg/mL concentration (or 5 mL for 1 mg/mL). Gently swirl until dissolved. Do not shake.
Draw 1 mL of solution using a 1 mL syringe (no needle needed for topical use). At 0.5 mg/mL, 1 mL contains 500 mcg. At 1 mg/mL, 1 mL contains 1,000 mcg. On a standard 1 mL syringe, draw to the 100 unit mark for a full 1 mL application.
Apply the solution directly to the scalp using the syringe tip. Distribute evenly across thinning zones. Massage gently for 30 seconds.
Allow 15 to 20 minutes of absorption time before applying any additional topicals (valproic acid, minoxidil, GHK-Cu). Do not wash hair for at least 4 hours.
If using microneedling (0.5 to 1.5 mm depth, 1 to 2 times per week), apply PTD-DBM within 15 minutes of needling while micro-channels remain open. This dramatically improves dermal papilla penetration.
Discard after 14 days. Keep lyophilized vials at minus 20 degrees Celsius for long-term storage.
0.5-1 mg/mL concentration; 1 mL per session (500-1,000 mcg); penetration limited by intact skin barrier
Reconstitute 5 mg vial in 10 mL sterile water (0.5 mg/mL) or 5 mL (1 mg/mL). Apply with syringe tip or transfer to spray bottle. Part hair to expose scalp; apply directly to scalp tissue. Massage gently. No wash for 4h.
Same concentration (0.5-1 mg/mL); dramatically enhanced follicle-level delivery via micro-channels. Apply within 15 min of needling session while channels are open.
0.5mm depth for beginners; 1.0-1.5mm for experienced users targeting dermal papilla. 1-2x/week cadence maximum. Apply PTD-DBM immediately post-needling.
Concentration determined by prescribing physician; may include stabilizers or penetration enhancers absent in DIY reconstitution
Clinic protocols typically require consultation ($250+) plus monthly product cost. More consistent formulation than DIY; physician monitoring of scalp response. Limited availability: few practitioners familiar with topical peptide hair protocols.
Best-evidenced synergy. VPA inhibits GSK-3beta (downstream beta-catenin degrader); PTD-DBM removes CXXC5 suppression of Dvl (upstream Wnt activator). Mouse WIHN data confirms combination outperforms either agent alone. Only scientifically demonstrated synergy for this peptide.
0.1-0.3% VPA topical applied after PTD-DBM (15-20 min gap); daily application. Source from compounding pharmacy.
Complementary scalp and follicle support without Wnt pathway overlap. GHK-Cu promotes dermal collagen, elastin, and scalp tissue health. Community commonly combines both in topical hair protocols. No pharmacological conflict.
Apply GHK-Cu first (lower MW), allow 10-15 min, then PTD-DBM
Entirely different mechanism (vasodilation / anagen phase extension via potassium channels). No pharmacological conflict with PTD-DBM CXXC5-Dvl disruption. Theoretically additive for a broad AGA approach.
Apply minoxidil at a separate time from PTD-DBM (2h gap minimum) to prevent formulation interference
May attenuate Wnt/beta-catenin pathway activation. Concurrent application to the same scalp areas may counteract PTD-DBM mechanism.
Additive Wnt activation may dysregulate the proto-oncogenic pathway. Topical VPA (low systemic absorption) is acceptable; systemic GSK-3beta inhibitors or high-dose lithium create unpredictable additive risk with insufficient safety data.
Pricing updated 2026-04-09
Wnt/beta-catenin is a proto-oncogenic pathway. That fact deserves attention before anything else. No formal carcinogenicity study has been conducted for PTD-DBM. Chronic activation of Wnt signaling is linked to several cancer types. Topical application limits systemic exposure, and no cancer signal appeared in mouse studies, but the absence of a long-term safety study is a genuine gap. Anyone with a personal or family history of Wnt-pathway cancers should exercise particular caution. No human clinical trial has been published. The total human evidence base consists of in vitro dermal papilla cell culture data. Side effect information comes entirely from animal models and community self-reports across a small user base (tressless.com, HairLossTalk forums, r/HairlossResearch). Scalp irritation and redness are the most commonly reported issues. These occur primarily in users combining PTD-DBM with microneedling, which creates micro-channels in the scalp. Irritation from microneedling alone can be difficult to distinguish from peptide-related reactions. Users running the VPA combination protocol report higher irritation rates than PTD-DBM alone. Increased scalp oiliness is mechanistically expected. CXXC5 is expressed in sebaceous glands, and blocking it may dysregulate sebum production. Several community reports describe new or worsening oiliness after 4 to 8 weeks of daily use. If seborrheic dermatitis develops, discontinue immediately. Allergic reactions to the peptide itself appear rare in community reports. No systemic side effects have been documented, consistent with minimal absorption from topical application. When to stop: new or changing scalp lesions of any kind (given the Wnt proto-oncogenicity concern), persistent dermatitis, significant folliculitis, or seborrheic dermatitis that worsens despite reducing application frequency. Any new scalp lesion warrants dermatologist evaluation. Contraindications: pregnancy or breastfeeding (no safety data), active scalp infections or open wounds, known hypersensitivity to PTD-DBM or formulation excipients, history of skin cancer or active malignancy, and children under 18.
Verify PTD-DBM dosing and safety with a second opinion
PTD-DBM is a ~2.5 kDa peptide with high susceptibility to enzymatic degradation and thermal instability. Few vendors maintain required cold chain (-20°C lyophilized; 2-8°C reconstituted, 14-day max). No consumer-accessible analytical test verifies concentration or purity. Cosmetic serums (InfiniWell-type, 0.002%) are 100-500x below research concentrations. Even correctly sourced product has unknown topical bioavailability in intact skin without microneedling.
| Test | When | Target |
|---|---|---|
| Scalp photography | Baseline, then monthly throughout protocol | — |
| Trichoscopy / dermatoscopy | Baseline and at week 12 (week 24 if continuing) | — |
| Scalp symptom self-assessment | Weekly throughout protocol | No new oiliness, lesions, dermatitis, or folliculitis. Discontinue if seborrheic dermatitis develops. |
Objective documentation of density changes. Standardize lighting, angle, and hair parting at every session for valid comparison.
Detects vellus-to-terminal conversion and early follicle density changes invisible to the naked eye. Recommended for WIHN protocol users.
CXXC5 expressed in sebaceous glands: chronic blockade may increase sebum or worsen seborrheic dermatitis. Early detection prevents escalation.
Scalp adjusts to topical application. No visible hair changes yet. Mild redness possible with microneedling. Wnt/β-catenin signaling begins to reactivate in follicular cells.
Early follicle stimulation may begin. Vellus (fine) hair density may increase in treated areas. Continued consistent application is critical for cumulative signaling effects.
Visible improvements in hair density and thickness reported in animal models at comparable timepoints. Terminal hair conversion from vellus hairs may begin. Best results seen with PTD-DBM + valproic acid combination.
Continued follicle maturation and hair cycle normalization. New follicle formation (neogenesis) possible in areas with microneedling. Application frequency can be reduced to every 10-15 days for maintenance.
Maintenance phase. Ongoing application at reduced frequency to preserve gains. Long-term human efficacy data is still limited: results extrapolated from preclinical models.
Weeks 1 through 4: Scalp adjustment, nothing visible. Wnt/beta-catenin signaling starts reactivating in follicular cells based on mouse model timelines, but you won't see or feel anything meaningful. Mild redness is common if you're microneedling. Some users notice increased scalp oiliness during this window. Weeks 5 through 8: Early follicle signaling may begin at the cellular level. Mouse data shows activation markers appearing in this window. Community reports still describe no visible changes for the majority of users. A few report reduced shedding, but no confirmed regrowth at this stage. Weeks 9 through 12: This is the peak response window in preclinical models. The mouse wound model showed visible new follicle formation at comparable timepoints with the PTD-DBM plus VPA combination. Most human users still report no visible change. A small minority describe subtle density increases or early vellus hair changes, not terminal hair. Months 4 through 6: Assessment time. Most non-responders stop around month 4. Users who continue report maintenance of any early gains. Very few describe terminal hair regrowth that competes with minoxidil or finasteride benchmarks. Application frequency can drop to every 10 to 15 days for maintenance. Months 6 and beyond: Maintenance phase for committed users. Long-term human efficacy data doesn't exist. Results at this stage are extrapolated from preclinical models. Ongoing application at reduced frequency preserves whatever Wnt signaling state was achieved.
Wnt/beta-catenin signaling begins reactivating in follicular cells per mouse timeline. No observable follicle changes at this stage in any model.
No visible changes. Users establish routine and assess scalp tolerance. Mild redness common with microneedling. Some notice increased oiliness.
Mouse data: early follicle activation markers appear in this window. Vellus hair density may increase in treated areas based on mouse model timeline extrapolation.
Still no visible changes for the majority. Rare users report reduced shedding. No confirmed regrowth reports at this stage.
Mouse wound model shows visible new follicle formation at comparable timepoint with PTD-DBM + VPA combination. Terminal hair conversion from vellus may begin.
Majority report no visible change. A small minority report subtle density increase. Most who will see any results note early vellus changes here: not terminal hair.
New follicle maturation and hair cycle normalization (if follicle neogenesis occurred). Mouse data shows continued density improvement in WIHN responders.
Most non-responders discontinue around month 4. Users who continue report maintenance of early gains. Very few report meaningful terminal hair regrowth vs. minoxidil or finasteride benchmarks.
Ongoing application to preserve Wnt signaling state. Reduced frequency (every 10-15 days) for maintenance per cycling protocol.
Long-term human efficacy data absent. Results extrapolated from preclinical models. Users at this stage typically committed to experimental stack despite uncertain outcomes.
Source: Estimated from general small peptide degradation kinetics; no specific PK study for PTD-DBM published. Topical residence time likely longer due to skin depot effect.
Loading the interactive decay curve.
PTD-DBM is classified as research-only. It holds no FDA approval for any indication, has no drug approval in any jurisdiction, and is not recognized as a dietary supplement. The peptide is sold by research chemical vendors for in vitro and preclinical research purposes. No compounding pharmacy currently lists PTD-DBM as a standard formulation. Select clinics offer custom topical preparations (approximately $250 consultation plus $200 per month based on community reports from HairLossTalk), but availability is extremely limited. WADA status has not been formally addressed for PTD-DBM, though topical peptides without systemic pharmacological activity are generally outside anti-doping scrutiny. Purchasing for personal research use is legal in most jurisdictions, but quality assurance is entirely on the buyer. Require a Certificate of Analysis with HPLC purity data from any vendor. This content is for educational and research reference only. It does not constitute medical advice, and no information here should be interpreted as a recommendation to use PTD-DBM for any purpose.
Peptide Schedule Research TeamReviewed Apr 20266 Citations
